PHARMACOGENOMICS OF MDR1 IN PATIENTS WITH CYSTIC FIBROSIS (CF)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The renal clearance of a number of compounds appears to be increased in patients with cystic fibrosis. In-vitro and animal data indicate that upregulation of P-glycoprotein within the renal tubules may account for the increased clearance in this population as a compensatory mechanism for the defect in the cystic fibrosis transmembrane regulatory gene (CFTR). The purpose of this study is to compare the pharmacokinetics of a P-gp probe, fexofenadine in patients with CF and age-matched control subjects. In addition, MDR1 genotype-phenotype relationships will be evaluated.